These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23114587)

  • 1. Biologics-induced autoimmune diseases.
    Perez-Alvarez R; Pérez-de-Lis M; Ramos-Casals M;
    Curr Opin Rheumatol; 2013 Jan; 25(1):56-64. PubMed ID: 23114587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune diseases induced by biological agents: a double-edged sword?
    Ramos-Casals M; Roberto-Perez-Alvarez ; Diaz-Lagares C; Cuadrado MJ; Khamashta MA;
    Autoimmun Rev; 2010 Jan; 9(3):188-93. PubMed ID: 19854301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).
    Pérez-De-Lis M; Retamozo S; Flores-Chávez A; Kostov B; Perez-Alvarez R; Brito-Zerón P; Ramos-Casals M
    Expert Opin Drug Saf; 2017 Nov; 16(11):1255-1271. PubMed ID: 28854831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune diseases induced by TNF-targeted therapies.
    Ramos-Casals M; Brito-Zerón P; Soto MJ; Cuadrado MJ; Khamashta MA
    Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):847-61. PubMed ID: 19028367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infections and autoimmune diseases.
    Bach JF
    J Autoimmun; 2005; 25 Suppl():74-80. PubMed ID: 16278064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.
    Ramos-Casals M; Perez-Alvarez R; Perez-de-Lis M; Xaubet A; Bosch X;
    Am J Med; 2011 May; 124(5):386-94. PubMed ID: 21531225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Physiopathologic relationship between interstitial cystitis and rheumatic, autoimmune, and chronic inflammatory diseases].
    Lorenzo Gómez MF; Gómez Castro S
    Arch Esp Urol; 2004; 57(1):25-34. PubMed ID: 15119315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety issues with biological therapies for inflammatory bowel disease.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticytokine therapy in systemic lupus erythematosus.
    Yoo DH
    Lupus; 2010 Oct; 19(12):1460-7. PubMed ID: 20947558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases.
    Borchers AT; Leibushor N; Cheema GS; Naguwa SM; Gershwin ME
    J Autoimmun; 2011 Dec; 37(4):273-88. PubMed ID: 21907543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.
    Atzeni F; Sarzi-Puttini P; Doria A; Iaccarino L; Capsoni F
    Autoimmun Rev; 2005 Mar; 4(3):144-52. PubMed ID: 15823500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to manage infections in the era of biologics?
    Saraceno R; Chimenti S
    Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced autoimmunity.
    Dedeoglu F
    Curr Opin Rheumatol; 2009 Sep; 21(5):547-51. PubMed ID: 19593142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Useful examinations and therapies in immunologic diseases].
    Martenet AC
    Klin Monbl Augenheilkd; 1993 May; 202(5):474-8. PubMed ID: 8377420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of B cells for rheumatic autoimmune diseases.
    Engel P; Gómez-Puerta JA; Ramos-Casals M; Lozano F; Bosch X
    Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically validated approaches to the treatment of autoimmune diseases.
    Carter PH; Zhao Q
    Expert Opin Investig Drugs; 2010 Feb; 19(2):195-213. PubMed ID: 20050823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.